A Comparison of the Exponential Decay Slope between PEG-IFN alfa-2b/Ribavirin and IFN alfa-2b/Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Genotype 1b Infection and a High Viral Load | Citedby Results | Intervirology | Karger Publishers

Skip to Main Content

Skip Nav Destination

A Comparison of the Exponential Decay Slope between PEG-IFN alfa-2b/Ribavirin and IFN alfa-2b/Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Genotype 1b Infection and a High Viral Load

Intervirology (2004) 47 (2): 102–107.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

Goran Hauser
Tahany Awad
Jesper Brok
Kristian Thorlund
Davor Štimac
Mahasen Mabrouk
Christian Gluud
Lise Lotte Gluud

Cochrane Database of Systematic Reviews (2014) 2014 (2)

Complete Early Virological Response Was Highly Achieved by Double Filtration Plasmapheresis Plus IFN‐Beta Induction Therapy for HCV‐1b Patients With Relapse or No Response After Previous IFN Therapy

Toru Ishikawa
Kazuo Higuchi
Tomoyuki Kubota
Kei‐ichi Seki
Terasu Honma
Toshiaki Yoshida
Tomoteru Kamimura
Kazuyuki Tasaki
Shintarou Hirose
Yasushi Suzuki

Therapeutic Apheresis and Dialysis (2011) 15 (4): 400.

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C

Hiroaki Okushin

World Journal of Hepatology (2010) 2 (6): 226.

Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices

Hideyuki Nomura
Yugo Miyagi
Hironori Tanimoto
Masashi Higashi
Hiromi Ishibashi

Journal of Gastroenterology (2009) 44 (4): 338.

Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C

H. Nomura
Y. Miyagi
H. Tanimoto
H. Ishibashi

Journal of Viral Hepatitis (2009) 16 (5): 346.

Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha‐2b and ribavirin

Y. Asahina
N. Izumi
N. Umeda
T. Hosokawa
K. Ueda
F. Doi
K. Tsuchiya
H. Nakanishi
K. Matsunaga
T. Kitamura
M. Kurosaki
M. Uchihara
M. Higaki
S. Miyake

Journal of Viral Hepatitis (2007) 14 (6): 396.

Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C

M. SIMIN
J. BROK
D. STIMAC
C. GLUUD
L. L. GLUUD

Alimentary Pharmacology & Therapeutics (2007) 25 (10): 1153.

2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C

K.-I. Kim
S.-R. Kim
N. Sasase
M. Taniguchi
S. Harada
K. Kinoshita
S.-H. Kim
Y. Akimoto
M. Shikata
N. Kimura
S. Izawa
A. Ohtani
K. Nakao
M. Motojima
M. Kinoshita
M. Hirai
M. Ohzu
T. Hirooka
S. Nabeshima
F. Ishii
K. Tanaka
H. Hotta

Journal of Clinical Pharmacy and Therapeutics (2006) 31 (5): 441.